Skip to main content
. 2017 Jan 18;9(2):80–90. doi: 10.4254/wjh.v9.i2.80

Table 1.

Randomized Phase III trials in advanced hepatocellular carcinoma

Drug n (patients) OS (mo) HR
SOR/Exp arm
First line completed (Sorafenib standard)
Brivanib 1155 9.9/9.5 1.06
Sunitinib 1074 10.2/7.9 1.3
Sorafenib/Erlotinib 720 8.5/9.5 0.92
Linifanib 1035 9.8/9.1 1.04
Second line completed (placebo standard)
Brivanib 395 8.2/9.4 0.89
Everolimus 546 7.3/7.6 1.05
Ramucirumab 565 7.6/9.2 0.86

OS: Overall survival; SOR: Sorafenib arm.